Please assess the completion status of the following clinical trial:

Trial Title: Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced or recurrent breast cancer~* Resistant against anthracycline-based and taxane-based chemotherapy or difficult to continue the chemotherapy due to intolerable side effect(s)~* Resistant against trastuzumab or difficult to continue it due to intolerable side effect(s) when her-2 is positive~* ECOG performance status 0-2~* Life expectancy \> 3 months~* HLA-A\*0201~* Laboratory values as follows~  * 2000/mm3\<WBC\<15000/mm3~ * Platelet count\>100000/mm3~ * Bilirubin \< 3.0mg/dl~ * Asparate transaminase \< 150IU/L~ * Alanine transaminase \< 150IU/L~ * Creatinine \< 3.0mg/dl~* Able and willing to give valid written informed consent~Exclusion Criteria:~* Pregnancy(woman of childbearing potential:Refusal or inability to use effective means of contraception)~* Breastfeeding~* Active or uncontrolled infection~* Unhealed external wound~* Concurrent treatment with steroids or immunosuppressing agent~* Prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks~* Uncontrolled brain and/or intraspinal lesion(s)~* Decision of unsuitableness by principal investigator or physician-in-charge

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Peptide administered

Based on this trial design, predict the completion outcome and termination type (if applicable).